Immune checkpoints have been a focus of immunotherapy in the recent decade. Killer cell immunoglobulin-like receptors (KIR) and their cognate human leukocyte antigen (HLA) class I ligands have evolved as checkpoints to ensure self-tolerance of natural killer cells. Both KIR and HLA genetic profiles are potential biomarkers of immunotherapy outcome. Clin Cancer Res; 24(1); 3–5. ©2017 AACR.
See related article by Erbe et al., p. 189
from Cancer via ola Kala on Inoreader http://ift.tt/2EJpyej
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου